發送短信 : A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

   _____   __   __    _  _      ___     __   __  
  / ___//  \ \\/ //  | \| ||   / _ \\   \ \\/ // 
  \___ \\   \ ` //   |  ' ||  | / \ ||   \   //  
  /    //    | ||    | .  ||  | \_/ ||   / . \\  
 /____//     |_||    |_|\_||   \___//   /_//\_\\ 
`-----`      `-`'    `-` -`    `---`    `-`  --`